الفهرس 
Formulation and Evaluation of Oral Pulsatile Systems of an Anti-anginal Drug
ContentsOnly 14 pages are availabe for public view
 |  | from | 185 |  |  |
| | | from | 185 | | |
Abstract
The goal of any drug delivery system is to provide a therapeutic amount of a drug at a proper time or to a proper site of the body, so that the desired drug concentration could be achieved. Oral drug delivery is the most desirable and preferable route for the administration of therapeutic agents due to its unique advantages. It is widely used due to the ease of administration, low cost of therapy, high levels of patient compliance and flexibility in formulation. More efforts were performed to optimize this route for beneficial maximization and side effects minimization.Modified release drug delivery systemswere developed to enhance drug performance and to increase patient compliance.Diseases that follow circadian rhythm demand drug release after a defined lag time, the so-called pulsatile drug delivery systems (PDDSs). Recently, PDDSs have attracted many workers interested in the pharmaceutical field due to their marked impact on patient compliance, drug adherence and therapeutic efficiency in the management of disorders that follow circadian rhythm, such as angina pectoris. PDDSs are the approach for rapid and transient drug release immediately after lag time, providing both temporal and spatial drug delivery while preventing unwanted sustained drug exposure. PDDSs do not interrupt patients normal sleep patterns following an evening medication dose. Moreover, PDDSs help in preventing drug-drug interactions between co-administered drugs. PDDSs aim to decrease the dose size and dosing frequency, thereby decreasing adverse effects, improving tolerability, enhancing patient acceptance, and reducing the treatment cost